Severe gastrointestinal involvement in systemic sclerosis: Report of five cases and review of the literature

被引:56
作者
Jaovisidha, K
Csuka, ME [1 ]
Almagro, UA
Soergel, KH
机构
[1] Med Coll Wisconsin, Dept Med, Div Rheumatol, Milwaukee, WI 53226 USA
[2] Chulalongkorn Univ, Dept Med, Div Rheumatol, Bangkok 10110, Thailand
[3] Med Coll Wisconsin, Dept Pathol, Milwaukee, WI 53202 USA
[4] Med Coll Wisconsin, Dept Med, Div Gastroenterol & Hepatol, Milwaukee, WI 53202 USA
关键词
systemic sclerosis; scleroderma; gastrointestinal motility; gastrointestinal diseases;
D O I
10.1016/j.semarthrit.2004.08.009
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVE To review current literature on the gastrointestinal tract (GIT) manifestations of systemic sclerosis (SSc) and to report on 5 patients with severe gastrointestinal SSc. MATERIALS AND METHODS The clinical course and histopathology of 5 patients are described. A review of the medical literature registered in MedLine and PreMedLine databases from 1996 through mid-2004 was performed using the keywords systemic sclerosis and scleroderma and combining them with text words such as gastric, gastrointestinal, anorectal, colonic, and hepatic. RESULTS All 5 patients had severe GIT involvement: 4 with diffuse cutaneous SSc (dcSSc) and I with limited cutaneous SSc (IcSSc). Autopsy results of 2 patients who died from severe malnutrition and aspiration pneumonia are presented. Literature review includes involvement from oral cavity to anus with varying degrees of severity. Most GIT manifestations result from dysmotility secondary to infiltration of the gastrointestinal wall with fibrous tissue and can cause life-threatening malabsorption and malnutrition. Diagnostic tests, pathology, and treatments of GIT SSc are reviewed. CONCLUSIONS GIT involvement in SSc can be severely debilitating and even life-threatening. Although morbidity is inevitable, appropriate supportive treatment can prolong survival. RELEVANCE GI complications of SSc cause significant morbidity and mortality. (C) 2004 Elsevier Inc. All rights reserved.
引用
收藏
页码:689 / 702
页数:14
相关论文
共 97 条
[1]  
Adhami T, 2001, Semin Thorac Cardiovasc Surg, V13, P241, DOI 10.1053/stcs.2001.25313
[2]  
Akesson A, 1998, CLIN EXP RHEUMATOL, V16, P141
[3]  
Akimoto Sachiko, 1999, Journal of Dermatology (Tokyo), V26, P18
[4]   Treatment of non-ulcer dyspepsia:: a meta-analysis of placebo-controlled prospective studies [J].
Allescher, HD ;
Böckenhoff, A ;
Knapp, G ;
Wienbeck, M ;
Hartung, J .
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2001, 36 (09) :934-941
[5]   Clinical pharmacokinetics of tegaserod, a serotonin 5-HT4 receptor partial agonist with promotile activity [J].
Appel-Dingemanse, S .
CLINICAL PHARMACOKINETICS, 2002, 41 (13) :1021-1042
[6]  
Barbey Jean T., 2002, Journal of Cardiovascular Pharmacology and Therapeutics, V7, P65, DOI 10.1177/107424840200700202
[7]  
Bestetti A, 1999, J NUCL MED, V40, P77
[8]  
Boeckxstaens GE, 2002, AM J GASTROENTEROL, V97, P194
[9]  
BONAVINA L, 1995, ANN CHIR GYNAECOL, V84, P175
[10]  
Calamia KT, 2000, CLIN EXP RHEUMATOL, V18, P605